Amgen Inc. has raised its quarterly dividend by 6% to $2.52 per share, reflecting a 12% revenue growth year-over-year and ongoing investments in expansion across its therapeutic areas. However, the company faces significant stock market volatility, with recent options market activities indicating heightened investor scrutiny. Amidst pricing pressure and political challenges, Amgen remains committed to a hefty $3 billion investment in U.S. manufacturing, adding to its $40 billion investment since 2017.
“Amgen Inc. (AMGN) · need to pay close attention to the stock based on moves in the options market · true”
“Amgen Inc. · needs to pay close attention to · the stock · based on moves in the options market lately”
“Amgen Inc. · has · high implied volatility · May 15, 2026 $200 Call”
“Amgen Inc. · needs to pay attention · to stock based on moves in options market · true”
“Amgen Inc. · need to pay close attention to · the stock based on moves in the options market · true”
“Amgen Inc. · boosted · its quarterly dividend · by 6% to $2.52 per share”
“Amgen Inc. · has · 15 years of dividend increases · true”
“Amgen Inc. · reported · third quarter of 2025 revenue growth · 12% compared to last year”
“Amgen Inc. · expanded · in all four of its main therapeutic areas · true”
“Amgen Inc. · is sticking to its plan to invest · in US manufacturing · over $3 billion this year”
“Amgen Inc. · has invested · $40 billion in US manufacturing since 2017 · true”
“Amgen · is taking action · U.S. government · lower medicine costs for American patients”
